Stock Analysis

Top Growth Companies With High Insider Ownership On Euronext Paris September 2024

Published

As European inflation approaches the central bank's target and the French CAC 40 Index continues to show resilience, investors are increasingly focusing on growth opportunities within France. High insider ownership can be a strong indicator of confidence in a company's future, making it an important factor for those looking to invest in promising growth stocks.

Top 10 Growth Companies With High Insider Ownership In France

NameInsider OwnershipEarnings Growth
Groupe OKwind Société anonyme (ENXTPA:ALOKW)24.8%36%
VusionGroup (ENXTPA:VU)13.4%25.7%
Adocia (ENXTPA:ADOC)11.9%63%
Icape Holding (ENXTPA:ALICA)30.2%35.1%
Arcure (ENXTPA:ALCUR)21.4%27.5%
La Française de l'Energie (ENXTPA:FDE)19.9%31.9%
STIF Société anonyme (ENXTPA:ALSTI)16.4%28.5%
Munic (ENXTPA:ALMUN)29.2%149.2%
MedinCell (ENXTPA:MEDCL)15.8%93.9%
OSE Immunotherapeutics (ENXTPA:OSE)25.6%5.9%

Click here to see the full list of 22 stocks from our Fast Growing Euronext Paris Companies With High Insider Ownership screener.

Let's take a closer look at a couple of our picks from the screened companies.

Lectra (ENXTPA:LSS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Lectra SA provides industrial intelligence solutions for fashion, automotive, and furniture markets across Northern Europe, Southern Europe, the Americas, and the Asia Pacific with a market cap of €1.06 billion.

Operations: The company's revenue segments include €172.65 million from the Americas and €118.54 million from the Asia-Pacific region, with a segment adjustment of €209.13 million.

Insider Ownership: 19.6%

Revenue Growth Forecast: 10.4% p.a.

Lectra's revenue for the first half of 2024 was €262.29 million, up from €239.55 million a year ago, though net income declined to €12.51 million from €14.47 million. Despite this, analysts expect Lectra's earnings to grow significantly at 29.3% annually over the next three years, outpacing the French market average of 12.3%. The stock is trading at nearly half its estimated fair value and is projected to rise by 23.5%.

ENXTPA:LSS Earnings and Revenue Growth as at Sep 2024

MedinCell (ENXTPA:MEDCL)

Simply Wall St Growth Rating: ★★★★★☆

Overview: MedinCell S.A. is a pharmaceutical company in France that develops long-acting injectables across various therapeutic areas, with a market cap of €525.32 million.

Operations: MedinCell generates €11.95 million in revenue from its pharmaceuticals segment.

Insider Ownership: 15.8%

Revenue Growth Forecast: 46.2% p.a.

MedinCell's revenue is forecast to grow at 46.2% annually, significantly outpacing the French market. Expected to become profitable within three years, earnings are projected to grow by 93.95% per year. Strategic alliances with AbbVie and Teva bolster growth prospects, with potential milestone payments up to $2 billion and royalties on net sales. The stock trades at 86.9% below its estimated fair value, with analysts predicting a 22% price increase.

ENXTPA:MEDCL Earnings and Revenue Growth as at Sep 2024

VusionGroup (ENXTPA:VU)

Simply Wall St Growth Rating: ★★★★★★

Overview: VusionGroup S.A. offers digitalization solutions for commerce across Europe, Asia, and North America with a market cap of €2.20 billion.

Operations: The company's revenue primarily comes from installing and maintaining electronic shelf labels, generating €801.96 million.

Insider Ownership: 13.4%

Revenue Growth Forecast: 21.3% p.a.

VusionGroup's revenue is forecast to grow at 21.3% annually, significantly outpacing the French market. Earnings are expected to rise by 25.7% per year, driven by strategic partnerships like the recent one with Ace Hardware, which integrates VusionGroup’s digital shelf label technology across over 5,000 stores in the U.S., enhancing operational efficiencies and customer experience. Analysts agree on a potential 41% price increase for the stock.

ENXTPA:VU Ownership Breakdown as at Sep 2024

Turning Ideas Into Actions

Ready To Venture Into Other Investment Styles?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com